Yabo Announces Simplified Merger of Key Subsidiary SLK-V with SLK-M

1. Type of acquisition (e.g., merger, spin-off, acquisition, or share transfer): Merger

2. Date of occurrence: 115/6/9

3. Names of companies involved in the acquisition (e.g., the other party in a merger, newly established company in a spin-off, or target company in an acquisition or share transfer): 1. SLK Vertriebs GmbH (surviving company) 2. SLK Medical GmbH (dissolving company, subject to formal German merger procedures)

4. Counterparty in the transaction (e.g., the other party in a merger, the company receiving transferred business in a spin-off, or the counterparty in an acquisition or share transfer): SLK Medical GmbH

5. Is the transaction counterparty a related party? Yes

6. Relationship between the counterparty and the company (e.g., the company holds XX% investment in the investee), and explanation of why the acquisition or share transfer target is a related enterprise or related party, and whether it affects shareholder rights: Both SLK Vertriebs GmbH and SLK Medical GmbH are 100% owned subsidiaries of the group. This merger is intended to enhance management efficiency and overall operational effectiveness. It will not affect shareholder权益.

7. Purpose and terms of the acquisition, including reasons, consideration terms, and payment timing (Note 7): Purpose: Simplify investment structure and integrate operations In accordance with German legal procedures, the merger will be formally initiated after notarization. The dissolution of SLK Medical GmbH will be carried out in compliance with German procedures.

8. Expected benefits after the acquisition: Enhanced overall operational efficiency

9. Impact of the acquisition on net asset value per share and earnings per share: No impact

10. Type of consideration and source of funds for the acquisition: Since both SLK Vertriebs GmbH and SLK Medical GmbH are 100% owned subsidiaries of the group, no additional funding is required.

11. Share exchange ratio and its calculation basis: Not applicable

12. Opinion from accountants, lawyers, or securities underwriters on the unreasonableness of the transaction: Not applicable

13. Name of accounting firm, law firm, or securities underwriting company: Not applicable

14. Name of accountant or lawyer: Not applicable

15. License number of accountant or lawyer: Not applicable

16. Independent expert opinion on the reasonableness of the share exchange ratio or cash/other assets distributed to shareholders (including: 1. Methods, principles, or calculation methods used to determine the public acquisition price, and comparison with internationally accepted methods such as market price, cost, and discounted cash flow; 2. Comparison of financial status, profitability, and P/E ratios between the acquired company and listed peers; 3. If the acquisition price refers to a valuation report, description of the report and its conclusion; 4. If the acquirer’s repayment plan is secured by assets or shares of the acquired or surviving company, assessment of its impact on financial and operational soundness) (Note 7): Not applicable

17. Scheduled completion timeline (Note 7): In accordance with German legal procedures, the merger will be formally initiated after notarization on June 9, 2026. The dissolution of SLK Medical GmbH will be handled according to German procedures.

18. Matters concerning the surviving or newly established company assuming rights and obligations of the dissolved (or spun-off) company (Note 2): Upon completion of the merger, all assets, liabilities, and related rights and obligations of SLK Medical GmbH will be fully assumed by SLK Vertriebs GmbH.

19. Basic information of companies involved in the merger (Note 3): 1. SLK Vertriebs GmbH: Leasing and trading of medical devices 2. SLK Medical GmbH: Leasing and trading of medical devices

20. Matters related to spin-off (including valuation of business and assets to be transferred to existing or newly established companies; total number, type, and quantity of shares received by the spun-off company or its shareholders; matters related to capital reduction if applicable) (Note: Not applicable if not a spin-off announcement): Not applicable

21. Conditions and restrictions on future transfer of acquired shares: Not applicable

22. Plans after completion of the acquisition (including: 1. Intention and plan to continue business operations; 2. Whether dissolution, delisting, major organizational, capital, business plan, financial or production changes, arrangements for key personnel or assets, or any other material matters affecting shareholders’权益 will occur): No material matters affecting shareholders’权益 are expected.

23. Other important agreed terms: None

24. Other significant matters related to the acquisition: No material matters affecting shareholders’权益 are expected.

25. Did any directors object to this transaction? No

26. Information on directors with conflicts of interest in the acquisition transaction (name of individual director or legal entity director and its representative, nature of significant interest held by the individual or represented entity, including but not limited to actual or anticipated investment methods in other participating companies, shareholding ratio, transaction price, participation in management, and other investment terms; reasons for recusal or non-recusal, recusal status, and reasons for supporting or opposing the acquisition resolution) (Note 7): Not applicable

27. Does this involve a change in business model? No

28. Explanation of business model change (Note 4): Not applicable

29. Transaction history with the counterparty in the past year and expected in the next year (Note 5): Not applicable

30. Source of funds (Note 5): Since both SLK Vertriebs GmbH and SLK Medical GmbH are 100% owned subsidiaries of the group, no additional funding is required.

31. Other statements (Note 6): None